-
Mashup Score: 0Survival in Patients With Hematologic Cancers and COVID-19 - 6 month(s) ago
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Michael A. Thompson Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI Michael A. Thompson, Jenny Ahlstrom, Nathan W. Sweeney Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI, CrowdCare Foundation, Draper, UT, HealthTree, Lehi, UT Takeda, Sanofi and GSK for HealthTree Background: Multiple myeloma (MM) is a cancer of the immune system. Infection is a major cause of morbidity and mortality in MM. Vaccines are the first line of prevention
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 6 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0ASH 2017: Myeloma Patients Need a Flu Shot Booster! - HealthTree for Multiple Myeloma - 7 month(s) ago
Do multiple myeloma patients need a flu shot booster? Yes and then some! Research presented at ASH shows myeloma patients need more protection than others.
Source: healthtree.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Webprogram Unavailable - 7 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Vaccination in Multiple Myeloma: Review of Current Literature - 7 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu, Richards, Oaks, @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/5rB5mcSFAz
-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/s8O0qZr6Gk
-
-
Mashup Score: 0Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 - 7 month(s) ago
This viewpoint offers expert guidance for the use of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) to treat immunocompromised patients with acut
Source: academic.oup.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma - 7 month(s) ago
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS Sera from 238 patients with multiple myeloma (MM) undergoing SARS CoV-2 vaccination were analyzed. Antibodies against the SARS CoV-2 spike receptor-binding domain (RBD) and viral nucleocapsid were measured to detect serologic response to vaccine and environmental exposure to the virus. The capacity of antibodies to neutralize virus was quantified using pseudovirus neutralization assay and live virus neutralization against the initial SARS CoV-2 strain and the B1.617.2 (Delta) variant. RESULTS Vaccine-induced nAbs are detectable at much lower rates (54%) than estimated in previous seroconversion studies
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 - 7 month(s) ago
This cohort study examines the association between baseline immunosuppression and/or immunotherapy-based therapies with COVID-19 severity and cytokine storm in patients with cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/AI96OygInS